HOYA launches new advanced focus spectacle lenses for younger patients with presbyopia

News
Article

The new lenses are designed for young presbyopes, ranging in age from their late 30s to mid-40s, who may be either existing spectacle wearers or non-wearers.

Woman taking off glasses to read phone Image credit: AdobeStock/kostikovanata

Image credit: AdobeStock/kostikovanata

HOYA has announced the launch of its VisuPro All Day and VisuPro Flex advanced focus spectacle lenses to help patients that are beginning to experience age-related presbyopia.1 The new lenses are designed for young presbyopes, ranging in age from their late 30s to mid-40s, who may be either existing spectacle wearers or non-wearers, according to a news release.

“Uncorrected refractive error is the leading cause of vision impairment globally, yet current market offerings fail to address the unique needs of young presbyopes,” said John Goltermann Lassen, CEO at HOYA Vision Care, in the release. “Innovations to manage first presbyopic symptoms at the earliest stage are essential to minimize the impact of presbyopia on patients’ quality of life and ensure continued clarity of vision.” 

The lenses use HOYA’s Binocular Harmonization Technology (BHT) that considers the prescription for both eyes to calculate the prescription in the lenses for focusing, stability, and enhanced depth of vision. The Focus Max Optimization allows for additional vision support at close distance. The lenses can help reduce eye strain or visual fatigue when working with digital devices, which caters to the interest of younger patients with presbyopia, according to results from a HOYA survey. This research found that 53% of existing spectacle wearers and 60% of non-spectacle wearers between 36 and 44 years of age have increasing problems seeing clearly in the near distance and when using digital devices.1

"VisuPro lenses represent a major advancement in our approach to pre-presbyopia," said Griffith Altmann, chief technology officer at HOYA Vision Care, in an exclusive quote for Optometry Times. "By focusing on patients in the early stages of the condition, we’re offering a proactive solution that helps busy people beginning to experience symptoms continue to enjoy their lives to the full without compromising on visual comfort or performance. At HOYA, we’re committed to developing technologies that meet the evolving needs of patients, ensuring they can continue to enjoy clear and seamless vision at every age.”

Reference:
  1. HOYA launches VisuPro advanced focus spectacle lenses for patients experiencing first symptoms of presbyopia. News release. HOYA. April 2, 2025. Accessed April 3, 2025.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.